| Year ended 31 March 2026 | Year ended 31 March 2025 | |
| £000 | £000 | |
| Dividends from quoted companies | 87 | – |
| Money market funds* | 1,623 | 1,783 |
| Bank deposits* | 204 | 347 |
| Loans to unquoted companies | 239 | 1,014 |
| 2,153 | 3,144 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| Basic investment management fee | 632 | 1,895 | 2,527 | 567 | 1,701 | 2,268 |
| Performance-related fee | – | – | – | – | 321 | 321 |
| 632 | 1,895 | 2,527 | 567 | 2,022 | 2,589 |
| Year ended 31 March 2026 £000 | Year ended 31 March 2025 £000 | |
| Administrative and secretarial services | 82 | 79 |
| Directors’ remuneration | 134 | 140 |
| National Insurance contributions | 21 | 15 |
| Auditor’s remuneration – audit services | 73 | 76 |
| – non-audit services | – | – |
| Legal and professional expenses | 47 | 106 |
| Share issue promoter’s commission | 31 | 33 |
| Other expenses | 182 | 226 |
| 570 | 675 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Analysis of charge/(credit) for the year | ||||||
| UK corporation tax payable/(recoverable) on the return for the year | 216 | (216) | – | 852 | (852) | – |
| (b) Tax reconciliation | ||||||
| Return before tax | 951 | (2,487) | (1,536) | 1,902 | 6,464 | 8,366 |
| Return multiplied by the standard rate of UK corporation tax of 25.0% (2025: 25.0%) | 238 | (622) | (384) | 476 | 1,616 | 2,092 |
| Effect of: | ||||||
| Dividends not subject to tax | (22) | – | (22) | – | – | – |
| Capital returns not subject to tax | – | 133 | 133 | – | (787) | (787) |
| Movements in fair value of investments not subject to tax | – | 15 | 15 | – | (1,335) | (1,335) |
| Increase in surplus management expenses | – | 258 | 258 | – | 30 | 30 |
| Adjustment in respect of previous year | – | – | – | 376 | (376) | – |
| Tax charge/(credit) for the year | 216 | (216) | – | 852 | (852) | – |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Recognised as distributions in the | ||||||
| financial statements for the year | ||||||
| Previous year’s final dividend | 726 | 2,419 | 3,145 | 896 | 1,791 | 2,687 |
| Current year’s interim dividend | 254 | 4,061 | 4,315 | 442 | 3,318 | 3,760 |
| 980 | 6,480 | 7,460 | 1,338 | 5,109 | 6,447 | |
| (b) Paid and proposed in respect of the year | ||||||
| Interim paid – 1.7p (2025: 1.7p) per share | 254 | 4,061 | 4,315 | 442 | 3,318 | 3,760 |
| Final proposed – 1.3p (2025: 1.3p) per share | 757 | 2,521 | 3,278 | 660 | 2,198 | 2,858 |
| 1,011 | 6,582 | 7,593 | 1,102 | 5,516 | 6,618 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Level 1 | ||
| Quoted venture capital investments | 4,940 | 60 |
| Level 3 | ||
| Unquoted venture capital investments | 93,507 | 87,829 |
| 98,447 | 87,889 |
| Venture capital – unquoted Level 3 £000 | Venture capital – quoted Level 1 £000 | Total £000 | |
| Book cost at 31 March 2025 | 82,732 | 218 | 82,950 |
| Fair value adjustment at 31 March 2025 | 5,097 | (158) | 4,939 |
| Fair value at 31 March 2025 | 87,829 | 60 | 87,889 |
| Movements in the year: | |||
| Purchases at cost | 15,887 | – | 15,887 |
| Transfer on market listing* | (6,484) | 6,484 | – |
| Disposals – proceeds | (2,412) | (2,325) | (4,737) |
| – net realised gains/(losses) on disposal | (893) | 362 | (531) |
| Movements in fair value | (420) | 359 | (61) |
| Fair value at 31 March 2026 | 93,507 | 4,940 | 98,447 |
| Comprising: | |||
| Book cost at 31 March 2026 | 86,977 | 1,077 | 88,054 |
| Fair value adjustment at 31 March 2026 | 6,530 | 3,863 | 10,393 |
| 93,507 | 4,940 | 98,447 | |
| Equity shares | 78,776 | 4,940 | 83,716 |
| Preference shares | 2,463 | – | 2,463 |
| Interest-bearing securities | 12,268 | – | 12,268 |
| 93,507 | 4,940 | 98,447 |
| Valuation methodology of Level 3 investments | 31 March 2026 £000 | 31 March 2025 £000 |
| Revenue multiple | 62,738 | 54,354 |
| Cost and price of recent investment (calibrated and reviewed for impairment) | 26,120 | 20,143 |
| Earnings multiple | 4,649 | 13,301 |
| Net assets | – | 31 |
| 93,507 | 87,829 |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 62,738 | 0.1x – 8.0x | 3.3x | + 10% | 3,895 | 1.54 |
| -10% | (2,990) | (1.19) | ||||
| Earnings multiple | 4,649 | 2.5x – 9.2x | 5.8x | + 10% | 729 | 0.29 |
| -10% | (612) | (0.24) |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 54,354 | 0.25x – 8.0x | 4.5x | + 10% | 3,701 | 1.68 |
| -10% | (2,479) | (1.13) | ||||
| Earnings multiple | 13,301 | 4.0x – 8.0x | 7.0x | + 10% | 1,348 | 0.61 |
| -10% | (1,513) | (0.69) |
| Original cost £000 | Carrying value at 31 March 2025 £000 | Purchases in year £000 | Disposal proceeds £000 | Realised gain against carrying value £000 | |
| The Beauty Tech Group – partial disposal | 618 | 2,167 | – | 2,535 | 368 |
| Fresh Approach (UK) Holdings – disposal of entire holding | 873 | 309 | – | 867 | 558 |
| Thanksbox (t/a Mo) – disposal of entire holding | 1,524 | 364 | – | 820 | 456 |
| Buoyant Upholstery – partial disposal | 452 | 452 | – | 452 | – |
| Intuitive Holdings – deferred proceeds | – | – | – | 51 | 51 |
| CelLBxHealth (formerly Angle) – partial disposal | 67 | 18 | – | 12 | (6) |
| Adludio – in liquidation | 2,667 | 30 | – | – | (30) |
| Northrow – in administration | 1,406 | 70 | – | – | (70) |
| Newcells Biotech – in administration | 3,176 | 1,618 | 240 | – | (1,858) |
| 10,783 | 5,028 | 240 | 4,737 | (531) |
| Company | Registered office address | Investment type | Equity capital held % | Equity £000 | Debt £000 | Total investment cost £000 |
| Volumatic Holdings | Taurus House, Endemere Road, Coventry CV6 5PY | Unquoted | 25 | 216 | – | 216 |
| Biological Preparations Group | Unit 12 A-C Pantglas Industrial Estate, Bedwas, Caerphilly CF83 8DR | Unquoted | 23 | 561 | 1,605 | 2,166 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accrued income | 122 | 131 |
| Due from investment sales | 51 | 2,505 |
| Prepayments | 68 | 34 |
| 241 | 2,670 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Cash at bank | 7,316 | 7,062 |
| Money market funds | 32,000 | 31,000 |
| 39,316 | 38,062 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accruals and deferred income | 207 | 543 |
| 207 | 543 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Allotted and fully paid: | ||
| 252,148,197 (2025: 219,852,830) ordinary shares of 5.0p | 12,608 | 10,993 |
| Share premium £000 | Capital redemption reserve £000 | Capital reserve £000 | Revaluation reserve £000 | Revenue reserve £000 | |
| At 31 March 2025 | 62,633 | 1,468 | 47,177 | 4,939 | 868 |
| Premium on issue of ordinary shares | 23,763 | – | – | – | – |
| Share issue expenses | (850) | – | – | – | – |
| Shares purchased for cancellation | – | 585 | (6,398) | – | – |
| Realised on disposal of investments | – | – | (531) | – | – |
| Transfer on disposal of investments | – | – | (5,515) | 5,515 | – |
| Movements in fair value of investments | – | – | – | (61) | – |
| Management fee charged to capital net of associated tax | – | – | (1,679) | – | – |
| Revenue return after tax | – | – | – | – | 735 |
| Dividends recognised in the year | – | – | (6,480) | – | (980) |
| At 31 March 2026 | 85,546 | 2,053 | 26,574 | 10,393 | 623 |
| 31 March 2026 | 31 March 2025 | |||||
| Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | |
| Fixed-rate investments in unquoted companies | 12,268 | 9.8% | 2.4 | 10,308 | 10.4% | 1.8 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Cash and cash equivalents | 39,316 | 38,062 |
| 39,316 | 38,062 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Fixed-rate investments in unquoted companies | 12,268 | 10,308 |
| Cash and cash equivalents | 39,316 | 38,062 |
| Accrued dividends and interest receivable | 122 | 131 |
| 51,706 | 48,501 |
| 31 March 2026 | 31 March 2025 | Calculation | |
| Closing NAV per share (p) | 54.6p | 58.3p | a |
| Dividends paid out (p) | 3.0p | 2.9p | b |
| Adjusted NAV per share (p) | 57.6p | 61.2p | c = a + b |
| Opening NAV per share (p) | 58.3p | 57.3p | d |
| NAV total return (%) | (1.2)% | 6.8% | = (c / d) -1 |
| 31 March 2026 | 31 March 2025 | |
| Investment management fee | 2,527 | 2,268 |
| Other expenses | 570 | 675 |
| Total expenses (a) | 3,097 | 2,943 |
| Annualised average net assets (b) | 137,451 | 127,796 |
| Ongoing charges (a)/(b) (expressed as a percentage) | 2.25% | 2.30% |
| 31 March 2026 | 31 March 2025 | Calculation | |
| Closing price per share (p) | 53.5p | 53.5p | a |
| Dividends paid out (p) | 3.0p | 2.9p | b |
| Adjusted price per share (p) | 56.5p | 56.4p | c = a + b |
| Opening price per share (p) | 53.5p | 54.5p | d |
| Share price total return % | 5.6% | 3.5% | = (c/d) -1 |